Expert Insights

David Cescon, MD, PhD, discusses the similarities and differences in CDK4/6 inhibitors for patients with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.

Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.

Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...

Michel Ducreux, MD, reports results from a phase 3 trial showing FOLFIRINOX chemotherapy yields a significantly longer PFS vs gemcitabine for patients with locally advanced, unresectable pancreatic cancer.

Ana Aparicio, MD, discusses aggressive variants of metastatic castration-resistant prostate cancer, with a focus on treatment approaches for patients with androgen-indifferent disease.

Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...

Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.

Sara Hurvitz, MD, discusses the importance of right sizing early HER2 treatment for patients with HER2-positive breast cancer, a topic she presented at the 2022 Great Debates and Updates in Women's Oncology virtual meeting.

Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.